vs
AdvanSix Inc.（ASIX）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
Penumbra Inc的季度营收约是AdvanSix Inc.的1.1倍（$385.4M vs $359.9M），Penumbra Inc净利率更高（12.3% vs -0.8%，领先13.1%），Penumbra Inc同比增速更快（22.1% vs 9.4%），Penumbra Inc自由现金流更多（$68.0M vs $36.1M），过去两年Penumbra Inc的营收复合增速更高（17.6% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
ASIX vs PEN — 直观对比
营收规模更大
PEN
是对方的1.1倍
$359.9M
营收增速更快
PEN
高出12.8%
9.4%
净利率更高
PEN
高出13.1%
-0.8%
自由现金流更多
PEN
多$31.9M
$36.1M
两年增速更快
PEN
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $385.4M |
| 净利润 | $-2.8M | $47.3M |
| 毛利率 | 7.6% | 68.0% |
| 营业利润率 | -0.7% | 15.4% |
| 净利率 | -0.8% | 12.3% |
| 营收同比 | 9.4% | 22.1% |
| 净利润同比 | -892.9% | 40.6% |
| 每股收益（稀释后） | $-0.11 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXPEN
| Q4 25 | $359.9M | $385.4M | ||
| Q3 25 | $374.5M | $354.7M | ||
| Q2 25 | $410.0M | $339.5M | ||
| Q1 25 | $377.8M | $324.1M | ||
| Q4 24 | $329.1M | $315.5M | ||
| Q3 24 | $398.2M | $301.0M | ||
| Q2 24 | $453.5M | $299.4M | ||
| Q1 24 | $336.8M | $278.7M |
净利润ASIXPEN
| Q4 25 | $-2.8M | $47.3M | ||
| Q3 25 | $-2.6M | $45.9M | ||
| Q2 25 | $31.4M | $45.3M | ||
| Q1 25 | $23.3M | $39.2M | ||
| Q4 24 | $352.0K | $33.7M | ||
| Q3 24 | $22.3M | $29.5M | ||
| Q2 24 | $38.9M | $-60.2M | ||
| Q1 24 | $-17.4M | $11.0M |
毛利率ASIXPEN
| Q4 25 | 7.6% | 68.0% | ||
| Q3 25 | 6.8% | 67.8% | ||
| Q2 25 | 14.3% | 66.0% | ||
| Q1 25 | 14.2% | 66.6% | ||
| Q4 24 | 3.4% | 66.8% | ||
| Q3 24 | 14.4% | 66.5% | ||
| Q2 24 | 17.9% | 54.4% | ||
| Q1 24 | 0.9% | 65.0% |
营业利润率ASIXPEN
| Q4 25 | -0.7% | 15.4% | ||
| Q3 25 | -0.9% | 13.8% | ||
| Q2 25 | 7.7% | 12.0% | ||
| Q1 25 | 7.7% | 12.4% | ||
| Q4 24 | -3.9% | 13.6% | ||
| Q3 24 | 7.5% | 11.7% | ||
| Q2 24 | 11.5% | -27.0% | ||
| Q1 24 | -7.0% | 4.3% |
净利率ASIXPEN
| Q4 25 | -0.8% | 12.3% | ||
| Q3 25 | -0.7% | 12.9% | ||
| Q2 25 | 7.7% | 13.3% | ||
| Q1 25 | 6.2% | 12.1% | ||
| Q4 24 | 0.1% | 10.7% | ||
| Q3 24 | 5.6% | 9.8% | ||
| Q2 24 | 8.6% | -20.1% | ||
| Q1 24 | -5.2% | 3.9% |
每股收益（稀释后）ASIXPEN
| Q4 25 | $-0.11 | $1.20 | ||
| Q3 25 | $-0.10 | $1.17 | ||
| Q2 25 | $1.15 | $1.15 | ||
| Q1 25 | $0.86 | $1.00 | ||
| Q4 24 | $0.02 | $0.88 | ||
| Q3 24 | $0.82 | $0.75 | ||
| Q2 24 | $1.43 | $-1.55 | ||
| Q1 24 | $-0.65 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $186.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $1.4B |
| 总资产 | $1.7B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXPEN
| Q4 25 | $19.8M | $186.9M | ||
| Q3 25 | $23.7M | $321.0M | ||
| Q2 25 | $18.4M | $421.8M | ||
| Q1 25 | $8.3M | $376.1M | ||
| Q4 24 | $19.6M | $324.4M | ||
| Q3 24 | $17.3M | $280.5M | ||
| Q2 24 | $12.1M | $288.3M | ||
| Q1 24 | $20.6M | $223.1M |
股东权益ASIXPEN
| Q4 25 | $815.2M | $1.4B | ||
| Q3 25 | $818.2M | $1.4B | ||
| Q2 25 | $823.7M | $1.3B | ||
| Q1 25 | $794.4M | $1.2B | ||
| Q4 24 | $774.6M | $1.2B | ||
| Q3 24 | $766.4M | $1.1B | ||
| Q2 24 | $746.6M | $1.2B | ||
| Q1 24 | $713.2M | $1.2B |
总资产ASIXPEN
| Q4 25 | $1.7B | $1.8B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.5B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $68.0M |
| 自由现金流率自由现金流/营收 | 10.0% | 17.7% |
| 资本支出强度资本支出/营收 | 7.7% | 4.8% |
| 现金转化率经营现金流/净利润 | — | 1.83× |
| 过去12个月自由现金流最近4个季度 | $6.4M | $174.9M |
8季度趋势，按日历期对齐
经营现金流ASIXPEN
| Q4 25 | $63.7M | $86.5M | ||
| Q3 25 | $26.6M | $58.3M | ||
| Q2 25 | $21.1M | $44.9M | ||
| Q1 25 | $11.4M | $49.0M | ||
| Q4 24 | $64.2M | $51.1M | ||
| Q3 24 | $57.3M | $56.5M | ||
| Q2 24 | $50.2M | $22.6M | ||
| Q1 24 | $-36.2M | $38.3M |
自由现金流ASIXPEN
| Q4 25 | $36.1M | $68.0M | ||
| Q3 25 | $66.0K | $42.0M | ||
| Q2 25 | $-7.2M | $29.4M | ||
| Q1 25 | $-22.6M | $35.5M | ||
| Q4 24 | $29.8M | $45.7M | ||
| Q3 24 | $26.8M | $51.0M | ||
| Q2 24 | $16.7M | $18.1M | ||
| Q1 24 | $-71.6M | $32.5M |
自由现金流率ASIXPEN
| Q4 25 | 10.0% | 17.7% | ||
| Q3 25 | 0.0% | 11.8% | ||
| Q2 25 | -1.7% | 8.7% | ||
| Q1 25 | -6.0% | 11.0% | ||
| Q4 24 | 9.1% | 14.5% | ||
| Q3 24 | 6.7% | 16.9% | ||
| Q2 24 | 3.7% | 6.0% | ||
| Q1 24 | -21.3% | 11.7% |
资本支出强度ASIXPEN
| Q4 25 | 7.7% | 4.8% | ||
| Q3 25 | 7.1% | 4.6% | ||
| Q2 25 | 6.9% | 4.6% | ||
| Q1 25 | 9.0% | 4.2% | ||
| Q4 24 | 10.4% | 1.7% | ||
| Q3 24 | 7.7% | 1.8% | ||
| Q2 24 | 7.4% | 1.5% | ||
| Q1 24 | 10.5% | 2.1% |
现金转化率ASIXPEN
| Q4 25 | — | 1.83× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | 0.67× | 0.99× | ||
| Q1 25 | 0.49× | 1.25× | ||
| Q4 24 | 182.29× | 1.52× | ||
| Q3 24 | 2.57× | 1.91× | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
